Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 21, 2018 08:45 ET | Source: Abeona Therapeutics Inc.

Abeona Therapeutics Announces Upcoming Conference Participation

NEW YORK and CLEVELAND, Feb. 21, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene...
February 12, 2018 08:45 ET | Source: Abeona Therapeutics Inc.

Abeona Therapeutics Receives FDA Orphan Drug Designation for ABO-202 Gene Therapy Program in Infantile Batten Disease

NEW YORK and CLEVELAND, Feb. 12, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene...
February 08, 2018 14:00 ET | Source: Abeona Therapeutics Inc.

Abeona Therapeutics Reports Top-Line Data from Phase 1/2 Gene Therapy Trial in MPS IIIA

ABO-102 results presented at WORLDSymposium for Lysosomal Diseases show significant time- and dose-dependent reduction of underlying disease pathology, including decreased CSF and urine GAGs (HS...
February 07, 2018 08:45 ET | Source: Abeona Therapeutics Inc.

Abeona Therapeutics Reports on Initial Safety and Biopotency Signals in MPS IIIB Gene Therapy Clinical Trial

First-in-man AAV9-based gene therapy delivered by single intravenous injection targeting central nervous system and peripheral manifestations of MPS IIIB.ABO-101 is well tolerated and demonstrates...
February 02, 2018 08:54 ET | Source: Abeona Therapeutics Inc.

Abeona Therapeutics Announces Upcoming Presentations at the 14th Annual WORLDSymposium

NEW YORK and CLEVELAND, Feb. 02, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene...
January 29, 2018 08:45 ET | Source: Abeona Therapeutics Inc.

Abeona Receives FDA Regenerative Medicine Advanced Therapy Designation for EB-101 Gene Therapy in Epidermolysis Bullosa

First gene therapy RMAT designation for Epidermolysis BullosaEnables accelerated approval path and real world data usage NEW YORK and CLEVELAND, Jan. 29, 2018 (GLOBE NEWSWIRE) -- Abeona...
December 20, 2017 08:45 ET | Source: Abeona Therapeutics Inc.

Abeona Therapeutics Enrolls First Patient in ABO-101 Phase 1/2 Clinical Trial for MPS IIIB

NEW YORK and CLEVELAND, Dec. 20, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene and cell...
November 15, 2017 08:25 ET | Source: Abeona Therapeutics Inc.

Abeona Reports Third Quarter 2017 Financial Results and Recent Business Highlights

Investor Conference Call to be held Monday, November 20th at 10:00 am ETGlobal enrollment continues in ABO-102 trial for MPS IIIAScreening initiated in ABO-101 Phase 1/2 trial for MPS IIIBPivotal...
November 13, 2017 08:45 ET | Source: Abeona Therapeutics Inc.

Abeona Management to Present at Multiple Conferences in November

NEW YORK and CLEVELAND, Nov. 13, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene...
November 09, 2017 08:45 ET | Source: Abeona Therapeutics Inc.

Abeona Enrolls First Subject in Spain in Ongoing Phase 1/2 Clinical Trial in MPS IIIA

Company Opens European Subsidiary in Spain to Support Global Clinical DevelopmentNine subjects at global clinical sites enrolled to date with more than 2,000 days cumulative follow up assessed NEW...